Skip to main content
. 2018 Mar 20;15(5):7563–7570. doi: 10.3892/ol.2018.8301

Figure 4.

Figure 4.

miR-204 inhibits formation of cancer-initiating cells and reverses TMZ resistance in U251MG-R cells. (A) qPCR for miR-204 in U251MG and U251MG-R cells. U6 was the loading control (n=3). (B) qPCR for miR-204 in U251MG-R cells transfected with pre-miR-204 and control miR (mock). β-actin was the loading control (n=3). (C) Sphere growth for U251MG-R cells transfected with pre-miR-204 and control miR (mock). Scale bar, 200 µm (n=3). (D) MTT assay for cell viability in U251MG-R cells. U251MG-R cells transfected with pre-miR-204 and control miR (mock) were untreated or treated with TMZ. (E) Western blotting for STAT3, MDM2, CD133 and MET in U251MG-R cells transfected with pre-miR-204 and control miR (mock). β-actin was the loading control (n=3). TMZ, temozolomide; STAT3, Signal transducer and activator of transcription 3; MDM2, Mouse double minute 2 homolog; CD133, Prominin-1; MET, Tyrosine-protein kinase Met; miR, microRNA; R, resistant; PCR, polymerase chain reaction; RT, reverse transcription; q, quantitative.